한글목차

SDN-037은 미국 FDA가 승인한 백내장 수술 후 눈의 통증과 염증에 대한 새로운 장시간 지속형(1일 2회) 안과용 스테로이드 제제입니다. 현재 시판되고 있는 스테로이드 점안제는 4-6시간마다 투여해야 하는데, SPARC의 제제는 투약의 편의성뿐만 아니라 유백색으로 투약 후 시야가 흐려지는 시판 제제에 비해 투명합니다.

앞으로 수년간 급성 안구통증 시장 시나리오는 세계에서 광범위한 조사와 의료비 지출 증가로 인해 변화할 것입니다. 각 업체들은 질환을 치료/개선하기 위한 새로운 접근 방식에 초점을 맞춘 치료법을 개발하고, 과제를 평가하고, SDN-037의 우위에 영향을 미칠 수 있는 기회를 모색하고 있습니다. 급성 안구통증에 대한 다른 신흥 제품들이 SDN-037과 치열한 시장 경쟁을 벌일 것으로 예상되며, 가까운 시일 내에 후발주자 신약이 출시될 경우 시장에 큰 영향을 미칠 것으로 예상됩니다.

주요 8개국의 SDN-037 시장에 대해 조사했으며, 시장의 개요와 2024-2032년 판매 예측 데이터, 경쟁 구도 및 국가별 동향 등을 제공하고 있습니다.

목차

제1장 리포트의 서론

제2장 급성안통에 대한 SDN-037의 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계 신규 치료법)

제5장 SDN-037 시장 평가

• 급성안통에 대한 SDN-037의 시장 전망
• 주요 8개국 시장 분석
  • 주요 8개국 시장에서 급성안통에 대한 SDN-037의 시장 규모
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국
  • 캐나다
  • 한국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

“"SDN-037 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about SDN-037 for acute ocular pain (AOP) in the eight major markets. A detailed picture of the SDN-037 for acute ocular pain in the 8MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Canada and South Korea for the study period 2019 -2032 is provided in this report along with a detailed description of the SDN-037 for acute ocular pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the SDN-037 market forecast analysis for acute ocular pain in the 8MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in acute ocular pain.

Drug Summary:

SDN-037 is a novel long-acting (twice-a-day) formulation of a US FDA-approved ophthalmic steroid for eye pain and inflammation after cataract surgery. Currently marketed steroidal eye drops requires administration every 4-6 h. Apart from providing dosing convenience, SPARC's formulation is clear compared to a marketed formulation which is milky, resulting in blurring of vision after administration.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the SDN-037 description, mechanism of action, dosage and administration, research and development activities in acute ocular pain.
• Elaborated details on SDN-037 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the SDN-037 research and development activities in acute ocular pain across the United States, Europe, Canada and South Korea.
• The report also covers the patents information with expiry timeline around SDN-037.
• The report contains forecasted sales of SDN-037 for acute ocular pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for acute ocular pain.
• The report also features the SWOT analysis with analyst views for SDN-037 in acute ocular pain.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SDN-037 Analytical Perspective by DelveInsight

In-depth SDN-037 Market Assessment

This report provides a detailed market assessment of SDN-037 for acute ocular pain in the eight major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Canada and South Korea. This segment of the report provides forecasted sales data from 2024 to 2032.

SDN-037 Clinical Assessment

The report provides the clinical trials information of SDN-037 for acute ocular pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for acute ocular pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence SDN-037 dominance.
• Other emerging products for acute ocular pain are expected to give tough market competition to SDN-037 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of SDN-037 in acute ocular pain.
• Our in-depth analysis of the forecasted sales data of SDN-037 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the SDN-037 in acute ocular pain.

Key Questions:

• What is the product type, route of administration and mechanism of action of SDN-037?
• What is the clinical trial status of the study related to SDN-037 in acute ocular pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SDN-037 development?
• What are the key designations that have been granted to SDN-037 for acute ocular pain?
• What is the forecasted market scenario of SDN-037 for acute ocular pain?
• What are the forecasted sales of SDN-037 in the eight major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, Canada and South Korea?
• What are the other emerging products available and how are these giving competition to SDN-037 for acute ocular pain?
• Which are the late-stage emerging therapies under development for the treatment of acute ocular pain?

Table of Contents

1. Report Introduction

2. SDN-037 Overview in Acute ocular pain

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. SDN-037 Market Assessment

• 5.1. Market Outlook of SDN-037 in Acute ocular pain
• 5.2. 8MM Analysis
  • 5.2.1. Market Size of SDN-037 in the 8MM for Acute ocular pain
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of SDN-037 in the United States for Acute ocular pain
  • 5.3.2. Market Size of SDN-037 in Germany for Acute ocular pain
  • 5.3.3. Market Size of SDN-037 in France for Acute ocular pain
  • 5.3.4. Market Size of SDN-037 in Italy for Acute ocular pain
  • 5.3.5. Market Size of SDN-037 in Spain for Acute ocular pain
  • 5.3.6. Market Size of SDN-037 in the United Kingdom for Acute ocular pain
  • 5.3.7. Market Size of SDN-037 in Canada for Acute ocular pain
  • 5.3.8. Market Size of SDN-037 in South Korea for Acute ocular pain

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options